Atlas FDA

MagtraceTM and Sentimag(R) Magnetic Locatization System

FDA premarket approval P160053 · decided 2018-07-24

Approval details

PMA number
P160053
Trade name
MagtraceTM and Sentimag(R) Magnetic Locatization System
Generic name
Lymph node location system during sentinel biopsy procedure
Applicant
Endomagnetics Ltd.,
Date received
2016-11-30
Decision date
2018-07-24
Days to decision
601 days
Decision code
APPR
Product code
PUV
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Cambridge
Statement
Approval for the MagtraceTM and Sentimag® Magnetic Localization System. The MagtraceTM and Sentimag® Magnetic Localization System is indicated to assist in localizing lymph nodes draining a tumor site, as part of a sentinel lymph node biopsy procedure, in patients with breast cancer undergoing a mastectomy. MagtraceTM is intended and calibrated for use ONLY with the Sentimag® system.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Magseed Pro Magnetic Marker System (K232865)Endomagnetics Ltd.,2024-06-28
Sentimag System (K222832)Endomagnetics Ltd.,2023-01-21
Magseed Magnetic Marker Systtem (K173587)Endomagnetics Ltd.,2018-02-16
Magseed Magnetic Marker System (K163541)Endomagnetics Ltd.,2017-01-13
Sentimag System, Sentimark Magnetic Marker Systerm (K153044)Endomagnetics Ltd.,2016-03-02